T he general approach to manage stable COPD is characterized by a stepwise increase in treatment, depending on the severity of the disease. None of the existing medications for COPD have been shown to modify the long term decline in lung function that is the hallmark of the disease. Therefore, pharmacotherapy in COPD is used to decrease symptoms and /or complications. Bronchodilator medications are central to the symptomatic management of COPD. They are given on an as needed basis or on a regular basis to prevent or reduce symptoms. The principal bronchodilator treatments are 2 agonists, anticholinergics, theophylline, and a combination of these drugs. Regular treatment with long acting bronchodilators is more effective and convenient than treatment with short acting bronchodilators, but more expensive. The addition of regular treatment with inhaled steroids to bronchodilator treatment is appropriate for symptomatic COPD patients with an FEV1 50% predicted (Stage : Severe COPD and Stage : Very Severe COPD) or repeated exacerbations (for example, more than 3 times during the last 3 years). Chronic treatment with systemic steroids should be avoided, if possible.
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